about
The Role of Cationic Polypeptides in Modulating HIV-1 Infection of the Cervicovaginal MucosaVirological features associated with the development of broadly neutralizing antibodies to HIV-1Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Current views on the potential for development of a HIV vaccine.HIV-Enhancing and HIV-Inhibiting Properties of Cationic Peptides and Proteins.Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and PotencyCharacterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop.Oral Delivery of a Novel Recombinant Streptococcus mitis Vector Elicits Robust Vaccine Antigen-Specific Oral Mucosal and Systemic Antibody Responses and T Cell Tolerance.Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFLInteraction between unrelated viruses during in vivo co-infection to limit pathology and immunityLongitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants.Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model.CXCL13 is a plasma biomarker of germinal center activity.Human Immunodeficiency Virus (HIV).Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem.Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.Polyvalent vaccine approaches to combat HIV-1 diversityImmunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.Identification and specificity of broadly neutralizing antibodies against HIVGerminal center enhancement by extended antigen availability.Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker TechniqueAn HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques[Human immunodeficiency virus: position of Blood Working Group of the Federal Ministry of Health].HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis.
P2860
Q27000032-CBBACD3D-C6A9-4425-8295-C5D87603A8FAQ27025177-CCDA5272-1CF8-4994-9046-C28768AE273FQ30234773-C0CDECA7-586B-404D-B457-4B2A82704D13Q30397595-BE43ED7E-0461-4BA8-92A2-876020199CB9Q33753950-42142FA4-ECFF-491B-BD18-37860A15DF1DQ33804531-CE355BD0-4FDD-4A09-82C4-A267CE8DEBCBQ35641369-3E3F8722-9B58-41C4-AF62-BEF1AEAF22FDQ35651494-7724498E-C566-4E8E-9DF1-7D17983846D5Q35855579-D8AC9DF8-3E12-4566-9F13-6667D682F6AFQ35913910-6E9173D5-F40A-45C6-9E12-BAB41A83B159Q36053149-ED40EF8C-8739-4641-ADCA-C6D6F745CAD8Q36246646-C1E84371-B7E9-4ADC-8256-1455D3C2C9B7Q36337888-13B7220E-CB56-4DA2-B27C-D1DE611F4F4FQ36684710-D0A668F9-1765-4878-8A4E-CCE2EFAC995EQ37045832-7B2E033B-8195-4086-AAEB-D3FA1067160FQ37634061-9A6A44D5-BA82-4F6B-8C11-A81CFA2F4242Q38405470-B0A1B63B-26D2-435C-B564-8C496C4BB5F0Q38753943-0A9F82D3-0F9C-4A80-ACA1-589C834DED30Q39108730-129B8687-7E5B-48A4-A464-9721F8F256D9Q39108735-40A7AA89-19B0-4A1C-9578-9FE2643ED300Q39108740-DD5F694C-B2E4-45B3-A50C-E3B749346D6FQ39108760-1EC5D3EC-3A82-43A0-9D9E-546071A51E61Q39108796-3618A036-29EB-4E80-8F61-400DFD409DF8Q39454581-E2EF35DC-7CCE-4978-BDD9-FFF33F44BB87Q40047250-E0F9D0A8-13DF-4993-B54D-B31E3B256817Q40639803-9816D2B5-5B0E-4663-9418-323DD86838D3Q40748041-263965CB-4D5D-449A-8A18-BAAFDDE75AFDQ40942917-C4EDB925-52E9-4B56-A9B5-6E78FD4000FDQ47555844-FED7D022-12AD-4E10-8AFE-656AFEDCE936
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Progress in HIV-1 vaccine development.
@ast
Progress in HIV-1 vaccine development.
@en
Progress in HIV-1 vaccine development.
@nl
type
label
Progress in HIV-1 vaccine development.
@ast
Progress in HIV-1 vaccine development.
@en
Progress in HIV-1 vaccine development.
@nl
prefLabel
Progress in HIV-1 vaccine development.
@ast
Progress in HIV-1 vaccine development.
@en
Progress in HIV-1 vaccine development.
@nl
P2093
P2860
P1476
Progress in HIV-1 vaccine development
@en
P2093
Barton F Haynes
Garnett Kelsoe
Georgia D Tomaras
Hua-Xin Liao
Laurent Verkoczy
M Anthony Moody
Munir Alam
P2860
P304
3-10; quiz 11
P356
10.1016/J.JACI.2014.04.025
P407
P577
2014-06-26T00:00:00Z